Hem/Onc Roundup: BRCA2 Mutation and Prostate Cancer, Cancer Drug Affects Cardio Health, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, a report indicated that where you live impacts your chances of surviving lung cancer, ruxolitinib is associated with worsening cardiometabolic health, and more.

Men with the BRCA2 mutation have an increased risk of prostate cancer compared with non-BRCA2 carriers and should undergo regular prostate-specific antigen testing, according to interim research from the IMPACT study, presented at the National Cancer Research Institute 2019 Cancer Conference. The results were also published in European Urology.

In the past decade, new lung cancer cases have decreased by 19% and five-year survival has increased by 26%, according to a promising report from the American Lung Association. Despite this, lung cancer remains the leading cause of death in the United States, and the chance of surviving the disease is largely dictated by where a person lives.

Secondary surgical cytoreduction followed by chemotherapy does not extend overall survival (primary endpoint) compared with chemotherapy alone in patients with platinum-sensitive, recurrent ovarian cancer, according to a study published in The New England Journal of Medicine.

Melanoma of the eye may soon be detected using a simple test, according to a study that appeared in Translational Vision Science & Technology.

Ruxolitinib, an oral JAK1/2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of myeloproliferative neoplasms, is associated with worsening cardiometabolic health, according to an article published in Scientific Reports.

In case you missed it, more hem/onc headlines are featured below: